Elcelyx was founded in 2010 with venture capital backing, based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they intensify the body’s natural food-driven signals that facilitate glucose regulation and create a sense of satiety.
The Elcelyx proprietary product candidates, NewMet for Type 2 diabetes and Lovidia for weight management, are composed of active pharmaceutical and dietary ingredients that have been safely used by patients and consumers for decades. Both programs represent reduced-risk, near-term blockbuster opportunities with longer-term growth potential into additional markets.
Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. The team is supported by premier investors and seasoned scientists and clinicians. The company utilizes a low fixed-cost virtual business model that leverages the use of an external network of consultants and contractors.
Elcelyx is headquartered in San Diego, California.